



# **Assessment of Ovulation in Polycystic Ovary Syndrome after Treatment with Tamoxifen**

A Thesis Submitted to the  
Faculty of Medicine at Cairo University  
In final Fulfillment of Master Degree in  
Obstetrics and Gynecology

**By**

**Maha Shaban Mohamed**

*M.B., B.Ch. (2004) – Faculty of medicine  
Misr University for science and technology*

**Supervised by**

***Prof. Dr. Sherif Abdel Rahman El Sharkawy***

Professor of obstetrics and gynecology  
Faculty of Medicine-Cairo University

***Dr. Ahmed Zakaria El Sheikhah***

Associate Professor of obstetrics and gynecology  
Faculty of Medicine-Cairo University

***Dr. Adel Mohammed Ali Nada***

Assistant Professor of obstetrics and gynecology  
Faculty of Medicine-Cairo University

FACULTY OF MEDICINE, CAIRO UNIVERSITY  
2012

# TABLE OF CONTENTS

**LIST OF TABLES**

**LIST OF FIGURES**

**LIST OF ABBREVIATIONS**

**ACKNOWLEDGMENTS**

**ABSTRACT**

**INTRODUCTION.....1**

**POLYCYSTIC OVARIAN SYNDROME (PCOS)**

**DEFINITION OF PCOS ..... 3**

**PATHOPHYSIOLOGY OF PCOS..... 6**

Insulin Resistance ..... 7

Neuroendocrine Defect .....10

Ovarian Defect.....12

Increased Peripheral Cortisol Metabolism .....15

Genetic of pcos..... 18

**DIAGNOSIS OF PCOS ..... 21**

Clinical Features .....22

Differential Diagnosis .....26

**TREATMENT OF PCOS ..... 31**

General Measures.....31

Medical Induction of Ovulation .....32

Surgical Induction of Ovulation .....38

**TAMOXIFEN**

Mechanism of action ..... 42

Uses ..... 43

Side effects ..... 44

**MATERIAL AND METHODS.....47**

|  |           |
|--|-----------|
| <b>RESULTS .....</b>                     | <b>50</b> |
| <b>CONCLUSIONS AND FUTURE WORK .....</b> | <b>68</b> |
| <b>REFERENCES.....</b>                   | <b>70</b> |
| <b>ARABIC ABSTRACT.....</b>              | <b>90</b> |

## LIST OF TABLES

| <b>TABLE No.</b> | <b>DESCRIPTION</b>  | <b>PAGE</b> |
|------------------|---|-------------|
| <b>Table 1:</b>  | Criteria for the diagnosis of polycystic ovary syndrome (PCOS)                    | <b>22</b>   |
| <b>Table 2:</b>  | Possible biochemical features   | <b>25</b>   |
| <b>Table 3:</b>  | Description of personal characteristics of study group 1 (Tamoxifen 10mg)         | <b>50</b>   |
| <b>Table 4:</b>  | Description of clinical characteristics of study group 1 (Tamoxifen 10mg)         | <b>50</b>   |
| <b>Table 5:</b>  | Description of complaints among study group 1 (Tamoxifen 10mg)                    | <b>50</b>   |
| <b>Table 6:</b>  | Description of outcome among study group 1 (Tamoxifen 10mg)                       | <b>51</b>   |
| <b>Table 7:</b>  | Description of personal characteristics of study group 2 (Tamoxifen 20mg)         | <b>51</b>   |
| <b>Table 8:</b>  | Description of clinical characteristics of study group (Tamoxifen 20mg)           | <b>51</b>   |
| <b>Table 9:</b>  | Description of complaints among study group 2 (Tamoxifen 20mg)                    | <b>52</b>   |
| <b>Table 10:</b> | Description of outcome among study group 2 (Tamoxifen 20mg)                       | <b>52</b>   |
| <b>Table 11:</b> | Description of personal characteristics of study group 3 (control)                | <b>53</b>   |
| <b>Table 12:</b> | Description of clinical characteristics of study group 3 (control)                | <b>53</b>   |
| <b>Table 13:</b> | Description of complaints among study group 3 (control)                           | <b>53</b>   |
| <b>Table 14:</b> | Description of outcome among study group 3 (control)                              | <b>54</b>   |
| <b>Table 15:</b> | Comparison between group 1 and 2 regarding age and other anthropometric measures. | <b>58</b>   |

## LIST OF TABLES CONT.

| <b>TABLE No.</b> | <b>DESCRIPTION</b>  | <b>PAGE</b> |
|------------------|---|-------------|
| <b>Table 16:</b> | Comparison between group 1 and 2 regarding complaints   | <b>59</b>   |
| <b>Table 17:</b> | Comparison between group 1 and 2 regarding lab outcome  | <b>59</b>   |
| <b>Table 18:</b> | Comparison between group 1 and 2 regarding clinical outcome                                     | <b>59</b>   |
| <b>Table 19:</b> | Comparison between tamoxifen groups and control group regarding age and anthropometric measures | <b>60</b>   |
| <b>Table 20:</b> | Comparison between tamoxifen groups and control group regarding complaints                      | <b>60</b>   |
| <b>Table 21:</b> | Comparison between tamoxifen groups and control group regarding lab and clinical outcome        | <b>61</b>   |
| <b>Table 22:</b> | Comparison between tamoxifen groups and control group regarding clinical outcome                | <b>62</b>   |

## LIST OF FIGURES

| <b>FIGURE NO.</b> | <b>DESCRIPTION</b>  | <b>PAGE</b> |
|-------------------|---|-------------|
| <b>Figure 1:</b>  | Ultrasound appearance of polycystic ovaries   | <b>13</b>   |
| <b>Figure 2:</b>  | Cut section of pcos   | <b>16</b>   |
| <b>Figure 3:</b>  | Description of age according to study group   | <b>54</b>   |
| <b>Figure 4:</b>  | Description of weight according to study group  | <b>55</b>   |
| <b>Figure 5:</b>  | Description of height according to study group  | <b>55</b>   |
| <b>Figure 6:</b>  | Description of FSH according to study group   | <b>56</b>   |
| <b>Figure 7:</b>  | Description of LH according to study group  | <b>56</b>   |
| <b>Figure 8:</b>  | Description of DHEAS according to study group   | <b>57</b>   |
| <b>Figure 9:</b>  | Description of progesterone according to study group  | <b>57</b>   |
| <b>Figure 10:</b> | Description of endometrial thickness according to study group   | <b>58</b>   |
| <b>Figure 11:</b> | Comparison between tamoxifen given patients group and control group regarding FSH, LH, progesterone levels, and endometrial thickness | <b>61</b>   |
| <b>Figure 12:</b> | Comparison between tamoxifen given patients group and control group regarding DHEAS levels  | <b>62</b>   |
| <b>Figure 13:</b> | Comparison between tamoxifen given patients group and control group regarding ovulation   | <b>63</b>   |
| <b>Figure 14:</b> | Comparison between tamoxifen given patients group and control group regarding leading follicle  | <b>63</b>   |

## LIST OF ABBREVIATIONS

|            |   |
|------------|---|
| ACTH       | Adreno Cortico Trophic Hormone  |
| ALT        | ALanine amino Transferase   |
| BMI        | Body mass index   |
| CAH        | Congenital Adrenal Hyperplasia  |
| CC         | Clomiphene citrate  |
| CL         | Corpus luteum   |
| CT         | Computed Tomography   |
| CYP        | CYtochrome P  |
| DHEAS      | Dihydroepiandrostenedione   |
| DM         | Diabetes mellitus   |
| DNA        | Deoxyribonuclear Acid   |
| EGF        | Epidermal growth factor   |
| ESHRE/ASRM | European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine |
| ER         | Estrogen Receptor   |
| FAH        | Functional Adrenal Hyperandrogenism   |
| FDA        | Food and Drug Administration  |
| FOH        | Functional Ovarian Hyperandrogenism   |
| FSH        | Follicle Stimulating Hormone  |
| GH         | Growth Hormone  |
| GnRH       | Gonadotropin-Releasing Hormone  |
| HCG        | human Chorionic Gonadotropin  |
| HMG        | Human Menopausal Gonadotropins  |
| HS         | High-Significant  |

## LIST OF ABBREVIATIONS CONT.

|                |   |
|----------------|---|
| IGF            | Insulin like Growth Hormone                   |
| LH             | Luteinising Hormone                           |
| LOD            | Laparoscopic Ovarian Drilling                 |
| MRI            | Magnetic Resonance Imaging                    |
| Nd-YaG         | Neodymium – Yttrium – Aluminum – Garent laser |
| NIH            | National Institutes of Health                 |
| NS             | Non- Significant                              |
| OHSS           | Ovarian Hyperstimulation Syndrome             |
| OWR            | Ovarian Wedge Resection                       |
| PAI            | Plasminogen Activator Inhibitor               |
| PCOS           | Polycystic ovary syndrome                     |
| PKC            | Protein Kinase C                              |
| PRL            | Prolactin                                     |
| S              | Significant                                   |
| SD             | Standard Deviation                            |
| SHBG           | Serum sex Hormone-Binding Globulin            |
| SPSS           | Statistical package for Social Science        |
| TGF- $\alpha$  | Transforming Growth Factor- $\alpha$          |
| TGF- $\beta$ 1 | Transforming Growth Factor- $\beta$ 1         |
| TSH            | Thyroid stimulating hormone                   |
| WHO            | World Health Organization                     |
| $\beta$ HSD    | $\beta$ Hydroxy Steroid Dehydrogenase         |



## *ACKNOWLEDGEMENTS*

*I would like to express my sincere thanks and deepest gratitude to Prof. Dr. Sherif Abdel Rahman El Sharkawy, Professor of obstetrics and gynecology, Faculty of Medicine Cairo University for his continuous interest, encouraging supervision, and valuable discussions during the process of this work.*

*I am greatly indebted to Dr. Ahmed Zakaria El Sheikhah, Associate Professor of obstetrics and gynecology, Faculty of Medicine Cairo University, for his precious help. I am very thankful for the time he devoted to the completion of this work. Also, I wish to express my deep thanks to Dr. Adel Mohammed Ali Nada, Assistant Professor of obstetrics and gynecology, Faculty of Medicine Cairo University, for his supervision, assistance, encouragement and valuable comments.*

*Finally, I want to thank all friends and colleagues, for their cooperation, help and support that was needed during the conduction of this study.*

*To my father, my mother,  
and All my family*

## Abstract

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 5% of all women. It occurs amongst all races and nationalities, is the most common hormonal disorder among women of reproductive age, and is a leading cause of infertility.

The principal features are weight problems, lack of regular ovulation and/or menstruation, and excessive amounts or effects of androgenic (masculinizing) hormones. The symptoms and severity of the syndrome vary greatly among women. While the causes are unknown, insulin resistance, diabetes, and obesity are all strongly correlated with PCOS.

Common symptoms of PCOS include: (i) Oligomenorrhea, amenorrhea (irregular, few, or absent menstrual periods). (ii) Infertility, generally resulting from chronic anovulation (lack of ovulation). (iii) Hirsutism (excessive and increased body hair, typically in a male pattern affecting face, chest and legs). (iv) Hair loss appearing as thinning hair on the top of the head. (v) Acne, oily skin, seborrhea. (vi) Obesity: one of two women with PCOS is obese. (vii) Depression and deepening of voice.

The use of tamoxifen for ovulation induction may be considered as an alternative to clomiphene citrate especially in cases resistant to clomiphene citrate. Sixty female patients with polycystic ovarian disease with mean age 30 years completed the study. All patients in the study were complaining of inability to conceive and menstrual irregularities in the form of oligomenorrhea or amenorrhea. These 60 patients are divided the three groups each group includes 20 patients. The three groups are namely: *Group A*: includes 20 patients who take 10 mg Tamoxifen per

day from 3-7 day of the menstrual cycle. *Group B*: includes 20 patients who take 20 mg Tamoxifen per day from 3-7 day of the menstrual cycle, and *Group C*: includes 20 patients were controlled.

The features of the three groups are described by, personal characteristics (age, weight, .. etc), the clinical characteristics (FSH, LH DHEAS level, ...etc), complaints (infertility, oligomenorrhea, and hirsutism), and finally compared regarding the clinical outcome (ovulation and presence of leading follicles). From our results we can conclude that: Tamoxifen 20 mg given patients group shows the success of ovulation by 30 %. Tamoxifen 10 mg given patients group shows the success of ovulation by 20 %. On the other hand, the Control group did not show any success.

### **Key Words :**

Luteinising Hormone - Standard Deviation - Protein Kinase C .

## INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. The overall prevalence among women in this age group is between 4% and 8%, although the prevalence may be as high as 30% in women with secondary amenorrhea, 75% in women with oligomenorrhea, and 90% in women with hirsutism (*Pedersen et al. 2007*).

In 1935, Stein and Leventhal published their report of seven women with amenorrhea, hirsutism, obesity, and enlarged polycystic appearing ovaries. Since then, much has been learned about this complex disorder (*Stein and Levanthal 1935*).

It is now well recognized that women with this syndrome not only have reproductive health issues but their metabolic and cardiovascular health is also affected. Until recently, there has been no universally accepted definition for PCOS. In 2003, an international consensus group proposed that the diagnostic criteria for PCOS are ovarian dysfunction evidenced by oligomenorrhea or amenorrhea and clinical evidence of androgen excess (e.g., hirsutism and acne) in the absence of other conditions that can cause these same signs and symptoms.

Polycystic ovaries, as defined by ultrasonography (the presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter, and/or ovarian volume > 10 mL) should also be considered as one of the possible diagnostic criteria for PCOS.

It is important to note that polycystic ovaries need not be present to make the diagnosis of PCOS. In fact, Clayton observed that 23% of normal women met the sonographic criteria for polycystic ovaries (*Clayton et al. 1989*).

## **Aim of the Work**

The aim of the present work is to:

- Assess the effect of tamoxifen on the follicle growth & ovulation rate.
- Compare 10 mg vs. 20 mg tamoxifen as dose for induction.
- Compare tamoxifen vs. controlled.

## DEFINITION OF PCOS

The classic syndrome originally was described in 1935 by Stein and Leventhal as the association of amenorrhea with polycystic ovaries in women, of whom about two thirds were hirsute, and one-half was obese.

The term PCOS was introduced upon recognition of a broader spectrum of clinical symptoms and ovarian histology, including stromal hyperplasia with multiple sub capsular follicles. (*Goldzieher et al., 1996*)

Approximately two-thirds of patients with classic PCOS have hirsutism (or hirsutism equivalents, acne vulgaris or pattern alopecia), two-thirds have an ovulatory symptoms (manifested as amenorrhea, oligomenorrhea, dysfunctional uterine bleeding, or unexplained infertility), and one half are obese.

Thus, only about one-third of classic cases have the full-blown clinical picture. The laboratory diagnostic criteria for classic PCOS require biochemical evidence of Hyperandrogenism with either a polycystic ovary by ultrasound or an increased serum level of lutenizing hormone (LH) to follicle-stimulating hormone (FSH) ratio. These criteria have proven not to necessarily coincide (*Colleen et al., 2005*).

In 1990, the National Institutes of Health (NIH) Conference on PCOS considered the implications of recent research findings for the diagnosis. Fifty percent to 60% of those present concurred that the criteria for PCOS should consist of chronic anovulation with clinical or biochemical signs of Hyperandrogenism that was not explained by other etiologies. This recognized the spectrum of the syndrome to include androgen excess in the absence of ultrasonographic and gonadotropic abnormalities (here termed non classic PCOS) (*Rosenfield, 1999*).